RHPS has just mentioned the above in an e-mail, they have gone up 240% today - started at 0.60 and finished up at 1.65. Look to be quite interesting.

Steady tabasco, all visual love making after 9.00pm please.....my kids might see:>))

Baler... visual love..is there any other? Do you make love without looking at your wife...you must be well equipped?.. Are you in the same room?...am I too nosey...why do I keep asking questions?

Don't be surprised if an RNS turns up to say that Drs John & Valerie Reader have sold to bring their holding below 3%, they founded SAR along with Dr Tim Mitchell.

I don't know why they would sell though!

I do hope not, that would make them go down down down. Just been reading again all about them and they are as you know into all sorts of things!!!!|! I wouldn't be surprised if that it is not too long before they have cracked one or two things - hopefully that is of course.

well - retrace was always a possibility - but this is aim lol! but personally it is the next rns or 2 i am looking fwd too more here - sar is on many peoples radar now - in fact has been for a little while - just intensifying now - and imo dont let val slip under the radar - like sar working towards similar goals - today at val 51m buy or 9% of the company delayed trade i believe - getting quite serious there and would not expect the sp to remain as low as it is for much longer apparently!! lol

good to see some quality alcoholics in here!! have a good evening all

Cheersh. Hic!

Call me silly...I have lumped on big time again today...those RNSs are shouting out...and if you imagine fear you shouldnt be in this game...good luck to all..

You are silly :-)

your silly!!

Very Silly!!!!!!!!!!!!!!

Thanks guys...I feel so much better now...

Sareum's CEO, Dr Tim Mitchell, commented: "These are exciting advances, demonstrating efficacy of our Chk1 compounds in several cancer models. Studies on additional models are on-going. We believe the results from the recently conducted studies will significantly enhance the licencing package...

Put a price on that guys?

3 monkies...what about getting a graph and some info on this thread at the top.

.0195p

1.95..............baler...i can be as silly as you...some would say sillier...is that a word?

It is, but I think it's more acceptable to use "more silly".

OK Skinny...i'm more silly...agreed? lol

Sorry - I'm just bored before the game tonight :-)

Have a read of this then skinny...

Sareum Holdings: An early stage drug group with a very interesting future
16th Feb, 11:20 am by Jamie Ashcroft
Sareum was formed in 2004, after the biotech bubble burst but before the financial crisis ravaged the capital markets. Sareum was formed in 2004, after the biotech bubble burst but before the financial crisis ravaged the capital markets.

The junior biotech space has been bubbling with excitement over the past two weeks. And in fact there appears to be the early signs of a renaissance in this cutting-edge sector.

If you are thinking of piling in ahead of the crowd, I have just a couple of words of warning.

Investing in these small-cap drugs stocks is not for the faint hearted. For every Amgen current value US$40 billion and growing - there are ten or more failures.

It is a roller coaster ride punctuated with failure more than success. So, you need to take a three-to-five year view.

That said, when these stocks take off, they do so spectacularly - you only have to look at recent performances of ValiRX (LON:VAL) and Sareum Holdings (LON:SAR), a company we here at Proactive Investors believe is a very interesting play in the biotech space.

It operates in oncology, which is the sexy end of drug discovery. Short of finding a cure for the common cold, a breakthrough discovery for cancer represents the Holy Grail for researchers and investors alike.

Hundreds of companies and thousands of scientists have devoted millions of man-hours to the quest. What we have, however, is a hodge-podge of life extending drugs and a couple of anti-cancer vaccines.

The urbane Jean-Pierre Garnier, the former boss of Glaxo, once said oncology products were progressing so fast that cancer could soon be managed as a chronic ailment rather than a life sentence.

Sadly, the latest wave treatments have failed back up this rather bold assertion.

However such is the interest in this particular area of medicine that any company making progress with a treatment for cancer is deemed hot property.

The performance of shares in Sareum is a graphic illustration of this.

It is in the early stages of developing a treatment for leukemia, a disease which kills over 200,000 people in the developed world each year.

Last week it published some pre-clinical data. Remember this is very, very early stage stuff yet the stock was like a runaway train.

The share price rocketed over 1,600 percent in just three days, rising from 0.275 to 4.79 pence.

Okay, the companys results look very positive. An in-vivo study of Sareum's Aurora+FLT3 Kinase programme, targeting the most common form of adult leukaemia, showed that the leukaemia had regressed to such an extent that no detectable cancer could be found in any of the cases treated - ten in total.

By comparison, leukaemia increased five to fifteen fold in the study examples treated without Sareum's compound.

Here we take a deeper look at the headline grabbing biotech junior. Proactive Investors spoke to Sareums founding director and chief executive Tim Mitchell.

Reinvigorated after weathering the financial storm

Sareum was formed in 2004, after the biotech bubble burst but before the financial crisis ravaged the capital markets.

It was spun out of Millennium Pharmaceutical when the American oncology specialist wrapped up its UK operations.

Mitchell, Millenniums director of structure-based discovery, founded the new business alongside Doctors John and Valerie Reader. Between them, Mitchell and the Readers, are the companys largest shareholders with 3.1 percent each.

Back then Sareum took a two-pronged approach.

It owned its own laboratories where it carried out in-house research on early pre-clinical stage drug compounds. Meanwhile it hired-out its spare capacity to work on other research on behalf of larger pharmaceutical firms.

The in-house research soon took a back seat and over three fairly successful years Sareum built up its service division. By 2007 it had 35 staff and it was turning over 35 million a year. Indeed the service division quickly grew in stature and at its peak it was handling more than 20 programmes for a variety of firms - including industry giants Roche and Johnson & Johnson.

Just before the financial crisis began to bite Sareum was almost breaking even, with its small losses being supported by modest capital raising in the AIM market.

The plan was always to use the service division revenues to support the in-house drug development until it could land a licensing deal and bring its own drug development to the fore.

For Sareum the tough years that ensued amid the recent financial turmoil presented a notable silver-lining, as it ultimately brought forward these plans.

The bottom fell out of the services market for a while, particularly in the US, and the AIM market wasnt in terribly good shape either, Mitchell said.

We were both struggling to earn money and struggling to raise money. We had to undergo a major rethink and restructuring.

Mitchell adds: This essentially brought forward our plans to concentrate solely on our internal research.

As the capital markets dried up and many of its peers went to the wall, Sareum sold of its service division for 720,000 in August 2008. It then striped back its remaining operations, closing its labs as part of the process.

In doing so it has created an efficient virtual organisation that outsources all the research work on its proprietary drugs compounds.

We operate out of an office now (rather than a lab), Mitchell said.

It keeps our costs low if we have to, but it is very flexible as we can turn-on the research as and when we require.

Indeed a quick glance at the stocks chart even before last weeks explosive rally suggests that Sareum has weathered the storm and after a relatively quiet transitional period it has once again burst into life.

The leukaemia study

With its newly restructured, and efficient, operation Sareum has been quietly getting its head down, progressing a number of pre-clinical research programmes into a variety of new drug compounds.

The latest results from the pre-clinical Aurora+FLT3 Kinase programme propelled the stock to more than a 1,600 percent gain last week.

Mitchell surmised that it was a standard pre-clinical test, using model systems where a cancer is induced and the drug compound is then applied to try and get rid of it. The tumour was measured every few days and compared with the untreated cases.

We got a very very good result, Mitchell said.

In the treated cases nothing was able to be found. Although that doesnt mean that the cancer wasnt there it was just too small to be detectable.

The experiment then continued with no further treatment to the tumour, to see whether it grows back.

Mitchell adds: It did grow back in eight of the ten cases, but not in two. This is still a great result.

The best result would be that the cancer never came back in all ten cases. But with another round of treatment we may get that ten out of ten.

Indeed the result was undoubtedly a game-changer, as least as far as investors were concerned.

Mitchell reckons the results stack up well against a number of more advanced drug candidates that are being developed in the clinic by his competitors.

He said that Sareum tries to compare the results as best it can against other similar drugs that are in development, although he notes that not all experimenting conditions are the same.

Against similar compounds that are already in early-stage clinical trials our result is at least as good, and while they might argue in our view theyre better, Mitchell said.

We see an advantage. Our results seem to be forming better than those that are out there in clinical trials, when they were at this stage.

However Mitchell stressed that there is still plenty of follow up work to do.


Full story...http://www.proactiveinvestors.co.uk/companies/news/25583/sareum-holdings-an-early-stage-drug-group-with-a-very-interesting-future

No dirty talk before 9.00 p.m. tonight tobasco, children might be watching. Thanks for posting the above saved me a job, as for a graph, I have not got a clue how to do one!!!!!!!!!! and I can't be a...d even learning how, not a brilliant day on this but early days. G & T time so good night - oh! my friend made a few bob out of LEG today in and out early so she is a happy bunny and she can't do graphs either. Cheers all.

Kim it might be home brew next week hahaha!!!!!!!!